Literature DB >> 25808729

Plasma folate levels in early to mid pregnancy after a nation-wide folic acid supplementation program in areas with high and low prevalence of neural tube defects in China.

Jufen Liu1, Lili Gao1, Yali Zhang1, Lei Jin1, Zhiwen Li1, Le Zhang1, Qinqin Meng1, Rongwei Ye1, Linlin Wang1, Aiguo Ren1.   

Abstract

BACKGROUND: Folic acid supplementation is recommended for all women of child-bearing age to prevent neural tube defects (NTDs). A nation-wide folic acid supplementation program was implemented in rural areas of China since 2009; however, changes in plasma folate levels in pregnant women were unknown.
METHODS: A cross-sectional survey was conducted in 2011 to 2012, with 1736 pregnant women enrolled, and results were compared with a previous survey in 2002 to 2004. A microbiological method was used to determine plasma folate levels. Preprogram and postprogram median plasma folate concentrations were compared while stratified by prevalence of NTDs and residence.
RESULTS: In the high NTD prevalence population, plasma folate concentration increased to 33.4 (18.7, 58.4) nmol/L in the postprogram sample, which is 2.9 times of the preprogram. In the low NTD prevalence population, plasma folate increased to 67.9 (44.5, 101.9) nmol/L, which is 1.9 times of the preprogram. Gaps remained in plasma folate levels with respect to prevalence of NTDs and residence. Folic acid supplementation has a strong impact on plasma folate concentrations. Earlier supplementation (before the last menstrual period), increased supplementation frequency and more total days of supplementation were associated with a higher plasma folate concentration as demonstrated in both the high- and low-prevalence populations.
CONCLUSION: Plasma folate levels among pregnant Chinese women increased dramatically after the nation-wide folic acid supplementation program in both rural and urban areas, and in populations of high and low NTD prevalence. The nation-wide program should have a component to ensure that supplementation begins before pregnancy.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  folate; folic acid supplementation; pregnancy; reproductive age; women

Mesh:

Substances:

Year:  2015        PMID: 25808729     DOI: 10.1002/bdra.23368

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  6 in total

1.  Folate of pregnant women after a nationwide folic acid supplementation in China.

Authors:  Xuejuan Zhang; Jufen Liu; Yongsheng Jin; Shuang Yang; Zhijiao Song; Lei Jin; Linlin Wang; Aiguo Ren
Journal:  Matern Child Nutr       Date:  2019-05-23       Impact factor: 3.092

2.  Prevention of neural tube defects with folic acid: The Chinese experience.

Authors:  Ai-Guo Ren
Journal:  World J Clin Pediatr       Date:  2015-08-08

3.  Prevalence of non-syndromic orofacial clefts: based on 15,094,978 Chinese perinatal infants.

Authors:  Dazhi Fan; Shuzhen Wu; Li Liu; Qing Xia; Guo Tian; Wen Wang; Shaoxin Ye; Lijuan Wang; Jiaming Rao; Xiao Yang; Zhen Yu; Lihong Xin; Song Li; Zhenghua Duan; Tianchen Zhang; Song Wu; Xiaoling Guo; Zhengping Liu
Journal:  Oncotarget       Date:  2018-01-13

4.  Sex differences in the prevalence of neural tube defects and preventive effects of folic acid (FA) supplementation among five counties in northern China: results from a population-based birth defect surveillance programme.

Authors:  Jufen Liu; Jing Xie; Zhiwen Li; Nicholas D E Greene; Aiguo Ren
Journal:  BMJ Open       Date:  2018-11-08       Impact factor: 2.692

5.  Periconceptional folic acid supplementation and risk of parent-reported asthma in children at 4-6 years of age.

Authors:  Jufen Liu; Zhiwen Li; Rongwei Ye; Jianmeng Liu; Aiguo Ren
Journal:  ERJ Open Res       Date:  2020-04-06

6.  Periconceptional Folic Acid Supplementation and the Risk of Spontaneous Abortion among Women Who Prepared to Conceive: Impact of Supplementation Initiation Timing.

Authors:  Yan-Yan Mao; Liu Yang; Min Li; Jun Liu; Qian-Xi Zhu; Yang He; Wei-Jin Zhou
Journal:  Nutrients       Date:  2020-07-29       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.